Glucagon-Like Peptide-1 (GLP-1) Agonist / 대한내과학회지
Korean Journal of Medicine
; : 9-13, 2014.
Artículo
en Coreano
| WPRIM (Pacífico Occidental)
| ID: wpr-69100
Biblioteca responsable:
WPRO
ABSTRACT
The prevalence of diabetes is increasing worldwide. Glycemic control has been shown to prevent microvascular complications. Many oral hyperglycemic drugs and insulin are being used in the treatment of diabetes, but the effects of those treatments are suboptimal. The two incretin hormones GLP-1 and GIP are released from L- and K-cells, respectively, in response to nutrient intake. GLP-1 stimulates glucose-dependent insulin release. Recently, incretin hormone-based therapies, including GLP-1 agonists and DPP-4 inhibitors, have been used as new treatment options to control glucose levels in patients with type 2 diabetes mellitus. The purpose of this article is to review the efficacy and safety of GLP-1 agonists in the treatment of type 2 diabetes.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Prevalencia
/
Diabetes Mellitus Tipo 2
/
Péptido 1 Similar al Glucagón
/
Incretinas
/
Glucosa
/
Insulina
Tipo de estudio:
Estudio de prevalencia
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2014
Tipo del documento:
Artículo